Effectiveness of erythropoietin in the treatment of patients with malignancies: Methods and preliminary results of a Cochrane review

Best Practice and Research: Clinical Haematology

Volumn 18, Issue 3 SPEC. ISS., 2005, Pages 449-454

  Bohlius, Julia F ^a   Langensiepen, Simon ^a   Engert, Andreas ^a   Schwarzer, Guido ^b   Bennett, Charles L ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cancer therapy; Recombinant human erythropoietin; Systematic review

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IRON; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLEEDING; CANCER SURVIVAL; CLINICAL TRIAL; COCHRANE LIBRARY; DATA ANALYSIS; DRUG EFFICACY; EMBASE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HEMATOCRIT; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN DETERMINATION; HUMAN; IRON DEFICIENCY ANEMIA; MEDLINE; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SYSTEMATIC REVIEW;

EID: 15844407275     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.01.022     Document Type: Review

References (11)

1. J.D. Rizzo A.E. Lichtin S.H. Woolf et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology J Clin Oncol 20 2002 4083-4107
2. Aronson N, Seidenfeld J, Piper M, Flamm RC, Hasselblad, V. Use of Erythropoietin in Oncology. Evidence Report/Technology Assessment No. 30. Prepared by the Blue Cross and Blue Shield Association Evidence-based Practice Center under Contract No. 290-97-0015. AHRQ Publ No. 01-E009. Rockville (MD): Agency for Healthcare Research and Quality; June 2001. http://www.ahrq.gov/.2001. Agency for Healthcare Research and Quality, US Department of Health and Human Services, 2101 East Jefferson Street, Rockville, MD 20852.
3. J. Seidenfeld M. Piper C. Flamm et al. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials J Natl Cancer Inst 93 2001 1204-1214
4. S. Langensiepen J. Bohlius J. Seidenfeld Erythropoietin for Patients with Malignant Disease (Protocol for a cochrane Review) 2003 Wiley Chichester, UK
5. K. Dickersin R. Scherer C.:. Lefebvre Identifying relevant studies for systematic reviews BMJ 309 1994 1286-1291
6. M.K. Parmar V. Torri L.:. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815-2834
7. M. Egger S.G. Davey M. Schneider C.:. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629-634
8. J. Bohlius S. Langensiepen G. Schwarzer J. Seidenfeld M. Piper C.L. Bennett et al. Erythropoietin for patients with malignant diseases(Cochrane Review) The Cochrane Library 2005 (1)
9. D. Moher D.J. Cook S. Eastwood I. Olkin D. Rennie et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses Lancet 354 1999 1896-1900
10. M. Henke R. Laszig C. Ruebe U. Schaefer K.D. Haase B. Schilcher et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial Lancet 362 2003 1255-1260
11. B. Leyland-Jones Breast cancer trial with erythropoietin terminated unexpectedly Lancet Oncology 4 2003 459-460